Perioperative Denosumab Versus Bisphosphonates for MIDLF Surgery in Patients With Osteopenia: A Short-Term Prospective Cohort Study

医学 德诺苏马布 围手术期 骨质疏松症 前瞻性队列研究 双膦酸盐 外科 骨量减少 不利影响 内科学 骨矿物
作者
Huang Changsheng,Lei Yue,Shijun Wang,Haolin Sun
出处
期刊:Global Spine Journal [SAGE Publishing]
卷期号:16 (2): 1102-1112 被引量:1
标识
DOI:10.1177/21925682251372500
摘要

Study Design Prospective Cohort Study. Objective To compare the effectiveness and safety of perioperative denosumab, bisphosphonates, and a control group in promoting lumbar fusion after midline lumbar fusion (MIDLF) surgery in patients with osteopenia or osteoporosis. Methods This prospective cohort study enrolled 54 patients with osteopenia or osteoporosis undergoing MIDLF surgery. Patients were divided into 3 groups: denosumab (60 mg subcutaneous injection), bisphosphonates (5 mg zoledronic acid intravenous infusion), and control (no anti-osteoporotic drugs, only calcium + vitamin D). Outcomes included fusion rates, clinical scores, bone metabolism markers, and adverse events. Results 54 patients were included in the study. Among them, 50 patients completed the 6-month postoperative follow-up. Due to the impact of the COVID-19 pandemic, only 29 patients completed the final follow-up. At 6 months, fusion rates were significantly higher in the denosumab (25% complete, 68.6% partial) and bisphosphonate (25% complete, 75% partial) groups compared to the control group (10.5% complete, 57.9% partial, P < 0.001). No significant difference was found between the 2 drug groups. Postoperative fever was more common in the bisphosphonate group (71.4%) than in the denosumab group (11.8%, P =0.004) and control (23.5%, P = 0.011) groups. Conclusions In the short-term follow-up, both denosumab and bisphosphonates significantly improved the early bone fusion rate after MIDLF surgery, with no significant difference observed between the two. Denosumab was associated with a lower incidence of postoperative fever, making it a recommended choice for perioperative anti-osteoporosis therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王小明发布了新的文献求助10
刚刚
刚刚
tang发布了新的文献求助30
刚刚
搜集达人的应助被坚定的采波采纳,获得10
1秒前
2秒前
希望天下0贩的0的应助被春天采纳,获得10
2秒前
左一完成签到,获得积分10
2秒前
3秒前
思源的应助被yyy采纳,获得10
3秒前
tang发布了新的文献求助10
3秒前
芝士完成签到 ,获得积分10
4秒前
5秒前
田様的应助被Yoyo采纳,获得10
5秒前
kai完成签到,获得积分20
5秒前
QT完成签到,获得积分10
5秒前
大模型的应助被Rr采纳,获得10
7秒前
7秒前
zoeyluo的应助被Marciu33采纳,获得10
7秒前
搜集达人的应助被叉叉采纳,获得10
8秒前
我是老大的应助被巧克力采纳,获得10
9秒前
smt发布了新的文献求助10
11秒前
11秒前
u635689完成签到,获得积分10
11秒前
u496670完成签到,获得积分10
12秒前
12秒前
u473030完成签到,获得积分10
12秒前
u553408完成签到,获得积分10
12秒前
13秒前
13秒前
u522844完成签到,获得积分10
14秒前
ecchaos完成签到 ,获得积分10
14秒前
u903509完成签到,获得积分10
14秒前
u154464完成签到,获得积分10
14秒前
u192236完成签到,获得积分10
14秒前
nana发布了新的文献求助10
15秒前
WX发布了新的文献求助10
16秒前
16秒前
QKD发布了新的文献求助20
16秒前
深情安青的应助被mate采纳,获得10
17秒前
u523475完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184240
求助须知:如何正确求助?哪些是违规求助? 9573297
关于积分的说明 21830585
捐赠科研通 7781300
什么是DOI,文献DOI怎么找? 3434285
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480814